Product
Donor Lymphocytes
1 clinical trial
4 indications
Indication
Acute Myeloid LeukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Myelodysplastic SyndromeIndication
Recurrent Acute Myeloid LeukemiaClinical trial
A Phase II Trial to Assess the Efficacy and Toxicity of SGI-110 With DLI for the Treatment of AML or MDS Relapsing After Allogeneic Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2024-12-31